Who is sponsoring NCT03690050?

NCT03690050 is sponsored by Belfast Health and Social Care Trust.

What drugs are being tested in NCT03690050?

Interventions in NCT03690050: Diode 577 nm subthreshold micropulse laser, Standard threshold laser (532 nm laser).

What condition does NCT03690050 study?

NCT03690050 studies Diabetic Macular Edema.

Is NCT03690050 still recruiting?

NCT03690050 is currently completed. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT03690050: DIAMONDS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison of Standard Laser With Micropulse Laser for the Treatment of Diabetic Macular Oedema.

Completed NA Last updated 6 May 2023

What this trial tests

NA trial testing Diode 577 nm subthreshold micropulse laser in Diabetic Macular Edema in 266 participants. Completed in 22 December 2020.

Timeline

1 November 2014

Primary endpoint
22 December 2020

22 December 2020

Quick facts

Lead sponsor	Belfast Health and Social Care Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	266
Start date	1 November 2014
Primary completion	22 December 2020
Estimated completion	22 December 2020
Sites	14 locations across United Kingdom

Drugs / interventions tested

Diode 577 nm subthreshold micropulse laser
Standard threshold laser (532 nm laser)

Conditions studied

Diabetic Macular Edema — all drugs for Diabetic Macular Edema →

Sponsor

Belfast Health and Social Care Trust — full company profile →

Who can join

18 and older, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DIAMONDS is a Randomised Controlled Clinical Trial that is being carried out in the UK to determine the clinical effectiveness and cost-effectiveness of micropulse laser, compared with standard laser, for the treatment of diabetic macular oedema.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
Lois N, Campbell C, Waugh N, Azuara-Blanco A, et al · · 2022 · cited 3× · PMID 36541393 · DOI 10.3310/szki2484
Subthreshold micropulse laser versus standard laser for the treatment of central-involving diabetic macular oedema with central retinal thickness of <400µ: a cost-effectiveness analysis from the DIAMONDS trial.
Mistry H, Maredza M, Campbell C, Lois N, et al · · 2023 · cited 1× · PMID 37852765 · DOI 10.1136/bmjopen-2022-067684

Verify or expand the search:

Other recruiting trials for Diabetic Macular Edema

Currently open trials in the same condition.

NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting

Other Belfast Health and Social Care Trust trials

Trials by the same sponsor.

NCT06985706 — Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser f · Phase 3 · recruiting
NCT06626984 — Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis · Phase 1, PHASE2 · not yet recruiting
NCT05414370 — Hyperoxia Induced Pulmonary Inflammation and Organ Injury: a Human in Vivo Model · NA · unknown
NCT05431491 — Feasibility of Slow Continuous UltraFiltration For Deresuscitation in Critically Ill Patients · NA · completed
NCT06036225 — PREPARE- Prehabilitation for Patients Awaiting Liver Transplantation: Feasibility and Acceptability Testing. · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03690050 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Belfast Health and Social Care Trust
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03690050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing